15 results about "Prilocaine" patented technology

The invention belongs to the technical field of medical and mechanical combinations, and discloses a high-permeability and low-sensitivity ripdicaine wound patch and a preparation method thereof.The high-permeability and low-sensitivity ripdicaine wound patch comprises a wound patch body, and the wound patch body is prepared from, by mass, 0.1%-0.4% of sodium hyaluronate, 1.5%-3.5% of lidocaine, 1.5%-3.5% of prilocaine, 3%-10% of solvent, 0.5%-8% of emulsifier, 2%-10% of humectant, 0.1%-5% of soothing agent, 0.1%-1.5% of stabilizer, 0.1%-1% of thickener and the balance water. According to the present invention, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, and the total amount of the raw materials is 100%. And the anesthetic has the advantages of quick effect taking, low sensitivity, capability of resisting moist heat sterilization and good stability.

The invention discloses a ripdicaine emulsifiable paste, and a preparation method and application of the ripdicaine emulsifiable paste. The preparation method of the lidocaine emulsifiable paste comprises the following steps: (1) melting a mixture of lidocaine, prilocaine and an emulsifier to prepare an oil phase; mixing the oil phase with water, and homogenizing for 28 to 50 minutes, so as to obtain primary emulsion; (2) homogenizing the carbomer solution, mixing the homogenized carbomer solution with an alkaline pH regulator, and regulating the pH value of the system to 8.2-9.2 to prepare a carbomer matrix; and (3) mixing the prepared milk, the carbomer matrix and the balance of water to prepare the ripdicaine emulsifiable paste. According to the present invention, the preparation method of the riprodicaine cream is optimized, such that the prepared riprodicaine cream has high stability, the stability of the lidocaine and the prilocaine is ensured during the preparation process, the content of the related substances is reduced, the ideal in vitro release effect is provided, and the local anesthesia effect is rapidly achieved.

The invention provides a method for simultaneously determining ritocaine and prilocaine in blood plasma based on a liquid chromatography-tandem mass spectrometry (LC-MSMS) technology. The specific operation of the method comprises the following steps: adding an internal standard solution and an organic solvent into a plasma sample, and ensuring full extraction of lidocaine and prilocaine through vortex mixing. And separating by using a centrifugal technology, and collecting supernate as a pretreated sample to be detected. An Eclipse Plus C18 chromatographic column is adopted for isocratic elution, effective separation of lidocaine and prilocaine is achieved, and then a sample is subjected to mass spectrometric detection. A standard curve is drawn based on the mass spectrum peak area ratio, a regression equation is obtained, and the concentration of lidocaine and prilocaine in the sample to be detected is obtained through calculation. The method has the characteristics of simplicity and convenience in pretreatment operation, low plasma consumption, short analysis time and high sensitivity, and is suitable for detection of lidocaine and prilocaine in plasma and clinical pharmacokinetic research of the lidocaine cream.

The invention discloses a detection method for simultaneous determination of lidocaine and prilocaine content in a lidocaine emulsifiable paste by high performance liquid chromatography, which comprises the following specific steps: step 1, taking lidocaine and prilocaine reference substances, and preparing a reference substance solution to detect the separation degree and theoretical plate number between lidocaine and prilocaine; step 2, taking the riptacaine cream, diluting with a solvent, and preparing a test solution; and step 3, acquiring chromatograms of the test solution and the reference solution under proper chromatographic separation conditions by applying high performance liquid chromatography and adopting a reversed-phase liquid chromatographic column, and quantitatively determining the content of lidocaine and prilocaine by an external standard method. The method overcomes the defects of complicated operation, poor durability, long detection time and poor specificity in the prior art, and has the characteristics of simplicity and easiness in operation, short running time, high detection efficiency, strong durability, strong specificity, good precision and high accuracy.

The invention provides ripdicaine nano-cream and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. According to the riprodicaine nano-cream provided by the invention, the riprodicaine-entrapped nanoparticles are dispersed in the cream matrix, and the riprodicaine-entrapped nanoparticles can control lidocaine and prilocaine to have a stable proportion, and can enable the riprodicaine nano-cream to have a good slow-release effect; the transdermal permeability of lidocaine and prilocaine is improved by utilizing the effect of the cream matrix. The result of the embodiment shows that the riptacaine nano-cream provided by the invention has good stability, permeability and slow release effect.

The invention relates to the technical field of medicines, and particularly discloses compound lidocaine cream as well as a preparation method and application thereof. The invention provides compound lidocaine emulsifiable paste. The compound lidocaine emulsifiable paste is specifically prepared from the following components in parts by weight: 22 to 26 parts of lidocaine, 22 to 26 parts of prilocaine, 13 to 17 parts of solubilizer, 9 to 11 parts of carbomer, 3 to 5 parts of sodium hydroxide and 0.02 to 0.06 part of penetration enhancer, the total amount is 1000 parts. The solubilizer is formed by mixing polyoxyethylene hydrogenated castor oil and poloxamer 188 in a weight ratio of (10-15): (1-4); the penetration enhancer is prepared by mixing L-ethyl lactate and oleic acid in a weight ratio of (1-4): (0.2-1). The compound lidocaine emulsifiable paste prepared by the invention has good safety, and the compound lidocaine emulsifiable paste has the effects of quicker effect taking, deeper anesthetic effect and longer duration time.

The invention discloses an in-vitro transdermal detection method of a ripdicaine drug. The in-vitro transdermal detection method of the riptacaine medicine comprises the following steps: a to-be-detected solution comprises a sample collected by transdermal treatment of the riptacaine medicine or the riptacaine medicine; high performance liquid chromatography-mass spectrometry equipment is adopted, and an internal standard method is combined to qualitatively or quantitatively detect lidocaine and prilocaine in a to-be-detected solution. The method has the advantages of short detection time, high detection efficiency, high specific detection property, high accuracy, high precision and high detection sensitivity.

The invention discloses an extraction method and a detection method of a ripdicaine medicine in skin. The extraction method of the ripdicaine medicine in the skin comprises the following steps: performing transdermal treatment on the ripdicaine medicine, removing the residual ripdicaine medicine on the surface of the skin, and performing liquid nitrogen freezing, crushing and ultrasonic extraction on the part of the skin coated with the ripdicaine medicine, thereby obtaining the ripdicaine medicine. The lidocaine and the prilocaine are fully extracted from the skin tissue by adopting a freezing and ultrasonic combined method, so that the accuracy of a detection result is ensured. The invention provides a safe and reliable detection method for detecting drug quality and clinical treatment effect. The invention further provides a rapid detection method, detection can be completed within 3.5 min, the detection efficiency is high, solvent consumption is reduced, the detection cost is reduced, the method can be suitable for high-throughput detection, the detection requirement of a large batch of samples is met, inter-batch detection errors are reduced, and the method further has high exclusive detection performance and is high in accuracy, precision and detection sensitivity.

The invention discloses a sodium hyaluronate wound dressing containing riptacaine and a preparation method of the sodium hyaluronate wound dressing, and relates to the technical field of medical dressings, the sodium hyaluronate wound dressing containing riptacaine comprises a base material and a dressing coated on the base material, the dressing is prepared from the following components in parts by weight: 0.1 to 5 parts of sodium hyaluronate, 0.1 to 5 parts of xanthan gum, 0.01 to 2 parts of preservative, 0.1 to 5 parts of lidocaine, 0.1 to 5 parts of prilocaine, 0.2 to 8 parts of hydrogenated castor oil, 1 to 20 parts of glycerol, 0.01 to 3 parts of azone substance, 0.1 to 2 parts of sodium dihydrogen phosphate and 29 to 98 parts of purified water, wherein the azone substance is laurocapram. According to the leidocaine-containing sodium hyaluronate wound dressing and the preparation method thereof, the sodium hyaluronate is introduced into the dressing of the leidocaine and the prilocaine, and the sodium hyaluronate has good moisturizing, repairing and biocompatibility, can provide a wet environment for a wound and can promote wound healing.

The invention relates to the field of medical application, in particular to a riptacaine pre-packaged application and a preparation method thereof. The lidocaine pre-packaged application is formed by packaging an application base material and anesthetic liquid together, and the anesthetic liquid is prepared from the following raw materials in parts by mass: 0.1 to 0.3 part of sodium hyaluronate, 0.1 to 0.3 part of a thickening agent, 7 to 13 parts of an alcohol penetration enhancer, 3 to 6 parts of a nonionic surfactant, 0.3 to 0.8 part of poloxamer and 1 to 3 parts of lidocaine, the anesthetic comprises the following components in parts by mass: 1-3 parts of prilocaine, 0.1-0.2 part of epsilon-polylysine, a pH regulator for regulating the pH value of the anesthetic liquid to 7.0-8.0, and the balance of water, totaling 100 parts by mass. According to the invention, by adding a small amount of epsilon-polylysine, the epsilon-polylysine not only has an antibacterial effect, but also can obviously improve the stability of the riptacaine liquid medicine, and through long-term storage and high-temperature acceleration experiments, the increase speed of related impurities is obviously slowed down, so that the reliability and safety of the pre-sealed riptacaine skin surface anesthesia application can be improved.

The invention discloses a positive ion saliva metabolite marker related to meningioma, a product and application of the positive ion saliva metabolite marker, and relates to the field of biological medicine. The positive ion saliva metabolite marker is prepared from one or more of 1-palmitoyl-2-glutaryl phosphatidylcholine, 2, 3, 5-triiodobenzene alcohol, beta-estradiol, cortisol, N-acetylcadaverine, prilocaine, octadecanoic acid, sulfamethoxam and rimsulfuron. The invention provides a kit which is used for detecting positive ion saliva metabolite markers related to meningioma and comprises a specific detection reagent. In addition, the invention also provides a computer program product which is specially used for evaluating meningioma. The products have good feasibility and accuracy, the risk of meningioma can be effectively evaluated, and a brand new powerful tool is provided for clinical diagnosis.

The present invention is within the technical field of pain-relief and relates to a pharmaceutical composition comprising at least one anesthetic agent selected from the group consisting of ropivacaine, bupivacaine, etidocaine, levobupivacaine, lidocaine, lignocaine, mepivacaine, articaine, dibucaine, levobupivacaine, prilocaine, benzocaine, chloroprocaine, cocaine, procaine, proparacaine, tetracaine and any pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof; at least one alkanolamine selected from the group consisting of triethanolamine, tripropanolamine and trimethanolamine; water; and optionally a pharmaceutically acceptable diluent, carrier and / or excipient. The present disclosure furthermore relates to the use of the composition for providing pain-relief, a method of treatment, a method of producing said pharmaceutical composition as well as a carbon quantum dot formed from components of the pharmaceutical composition.

The application discloses a preparation method of pramoxine, which comprises the following steps: taking 1,4-p-dibromobenzene and n-butanol as raw materials, and adopting cheap and easily obtained nickel salt as a catalyst, and under the action of catalytic amount of silane reagent, a ligand and an organic base, 1-bromo-4-butoxybenzene is synthesized through C-O coupling reaction; then, 1-bromo-4-butoxybenzene and 3-(4-morpholinyl)-1-propanol are subjected to C-O coupling reaction through the same method to obtain pramoxine. The preparation method has the characteristics of mild conditions, all the raw materials are commercially available and low in price, simple synthesis steps, high yield, high atom economy and the like, and is expected to realize industrialized production of pramoxine.

The invention relates to the technical field of drug detection, in particular to an exclusive, high-sensitivity, anti-interference and simple-operation quantitative detection method capable of simultaneously aiming at three isomeride nitrosamine impurities in a raw material drug prilocaine. According to the method disclosed by the invention, detection analysis is carried out by virtue of a liquid chromatograph-mass spectrometer, and quantitative detection of three nitrosamine impurities which are very close in structure and large in impurity limit requirement difference in the raw material medicine prilocaine is realized by screening liquid chromatography conditions, so that the quality controllability of the raw material medicine is improved, the carcinogenic risk can be reduced from the source, and the method is suitable for industrial production. The medication safety of a patient is ensured.